Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells.
Vicenti I, Dragoni F, Monti M, Trombetta CM, Giannini A, Boccuto A, Saladini F, Rossetti B, De Luca A, Ciabattini A, Pastore G, Medaglini D, Orofino G, Montomoli E, Zazzi M.
Vicenti I, et al. Among authors: pastore g.
J Gen Virol. 2021 Jan;102(1). doi: 10.1099/jgv.0.001499.
J Gen Virol. 2021.
PMID: 33048041